Helius Medical Soars 19.35% on CignaHealth Authorization

On June 19, 2025, Helius Medical's stock rose by 19.35% in pre-market trading, marking a significant surge that has garnered attention from investors and analysts.

Helius Medical Technologies, Inc. recently announced that CignaHealth has become the fifth major payer to authorize claims for payment for the PoNS Device. This authorization follows a similar move by Anthem MultiPlan, indicating a growing acceptance of the device within the healthcare industry. This development is a critical step towards wider adoption of the PoNS Device, as it enhances patient access and potential revenue streams for Helius Medical. The company's efforts in securing insurance reimbursement for the PoNS Device are expected to boost its market presence and financial performance. The authorization by CignaHealth is likely to have a positive impact on Helius Medical's share price, as it increases the device's accessibility to a broader patient base. This move is part of Helius Medical's broader strategy to expand the use of its innovative technology in the treatment of neurological conditions.